Expert Consensus on Real-World Use and Consumption Patterns of a Fixed-Dose Combination Foam for Psoriasis as a Reactive Management (RM) and Proactive Management (PAM) Regimen
ConclusionThis modified-Delphi study confirms that prescription of RM or PAM, with Cal/BD foam, is largely driven by patient-related factors and patient involvement is key to optimise outcomes. Real-world experiences captured in this study suggest that a PAM regimen does not increase overall consumption, and thus costs per patient for payers and prescribers, in comparison to RM.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Dermatology | Drugs & Pharmacology | France Health | Germany Health | Italy Health | Psoriasis | Skin | Spain Health | Study | Taclonex